Key Takeaways
- 2026 DSO EBITDA multiples range from 5x–14x, yet headline multiples rarely match the cash an owner receives after structure and tax.
- Typical transactions deliver 60–85% cash at close, with the balance split between rollover equity and earnouts that carry real risk and illiquidity.
- Normalized EBITDA add-backs, especially owner compensation, related-party rent, and personal expenses, can be some of the main drivers of enterprise value and receive intense buyer scrutiny.
- Buyer quality, capitalization, and post-close performance can directly affect the realizable value of rollover equity and can lead to price re-trades of 10–25% during diligence.
- McLerran & Associates runs a competitive sell-side process with vetted buyers to help owners maximize net proceeds. Explore what your practice may be worth in a free, confidential discovery call.
How Headline Multiples Become Real Cash at Closing
The multiple applied to your normalized EBITDA produces an enterprise value, yet enterprise value is not the wire that hits your account at closing. Every DSO deal divides that number into components, and only the cash portion is guaranteed at close.
In 2026, a standard DSO transaction structure can deliver 60–85% cash at close, 10–30% rollover equity into the DSO’s parent holding company, and a 1–3 year earnout tied to post-close EBITDA maintenance. Cash-at-close percentages often move inversely with practice scale. Smaller add-on acquisitions can deliver higher cash percentages because buyers require less founder alignment. Platform-tier deals can require deeper rollover to keep the selling dentist invested in the platform’s growth.
The table below maps 2026 multiple ranges to typical cash, equity, and earnout splits for a practice with $2 million in normalized EBITDA, and estimates indicative after-tax net proceeds assuming a well-structured asset sale with personal goodwill allocation. Notice how cash percentages generally decline as practice scale increases, while rollover equity grows as a share of total consideration. These figures are directional illustrations, not guarantees. Actual outcomes depend on practice-specific underwriting, buyer competition, and tax structure.
| Practice Scale / Buyer Type | Typical 2026 EBITDA Multiple Range | Typical Cash / Equity / Earnout Split | Indicative After-Tax Net Proceeds ($2M EBITDA Practice) |
|---|---|---|---|
| Solo GP, $500K–$1M EBITDA (small DSO add-on) | 5.5x–7.0x | 75–85% cash / 10–20% equity / 0–10% earnout | Not applicable at this EBITDA tier |
| 2–4 doctor group, $1M–$3M EBITDA (regional DSO add-on) | 7.0x–9.0x | 70–80% cash / 15–25% equity / 5–15% earnout | ~$10.5M–$14.4M enterprise value; ~$7.4M–$11.5M guaranteed cash at close before tax; after federal LTCG + NIIT (~23.8%), indicative net ~$5.6M–$8.8M on cash portion |
| Regional group, 5–9 offices, $3M–$8M EBITDA | 8.0x–11.0x | 65–75% cash / 20–30% equity / 5–15% earnout | Not directly comparable at $2M EBITDA; upper-tier multiples apply at higher EBITDA |
| Platform-scale, 10+ offices, $8M–$20M+ EBITDA | 10.0x–14.0x | 60–70% cash / 25–35% equity / 5–10% earnout | Not directly comparable at $2M EBITDA; platform multiples require platform-scale EBITDA |
Note: After-tax estimates assume a well-structured asset sale with personal goodwill allocation taxed at long-term capital gains rates. State taxes are additive. Consult a qualified tax advisor for practice-specific modeling.
Worked Example – Single-Location Add-On: A single-location general dentistry practice with $700K normalized EBITDA and strong hygiene retention receives a 6.0x offer, producing a $4.2M enterprise value. At an 80% cash-at-close structure, the owner receives $3.36M at closing, with the remainder split between rollover equity and a short earnout. The headline 6x multiple sounds straightforward. The guaranteed cash is materially less.
How Rollover Equity and Earnouts Change Your Effective Multiple
Rollover equity, the portion of deal consideration paid in shares of the DSO’s parent holding company rather than cash, can be the most consequential and least understood component of a DSO offer. Rollover equity typically represents 10–30% of total consideration for group practices, converting that share of the seller’s proceeds into an illiquid position in a private company the seller does not control.
Rolled equity in a private-equity-backed DSO is illiquid and exposed to dilution because the seller has no control over timing, future valuation, or whether additional equity raises occur before the next exit. Holding-company equity, as opposed to joint-venture equity that sits closer to the practice level and may generate distributions, typically sits behind the private equity sponsor’s preferred equity with liquidation preferences that must be satisfied before common equity holders receive anything.
Earnouts add a second layer of contingency. SRS Acquiom data indicate that earnouts outside life sciences pay approximately 21 cents on the dollar at expected value. A $500K earnout can be worth closer to $105K in probability-weighted terms. Earnout risk in DSO acquisitions sits almost entirely on the seller because the buyer controls operations post-close.
Worked Example – Multi-Location Platform: A five-location group with $3M normalized EBITDA receives a 9.0x offer ($27M enterprise value). The structure includes 68% cash ($18.36M), 25% rollover equity ($6.75M), and 7% earnout ($1.89M). The guaranteed cash at close is $18.36M before working-capital adjustments, indemnification escrows, and taxes. Sellers also face 10–15% indemnification escrows held for 12–24 months, which further reduce day-one liquidity. The rollover equity’s ultimate value depends entirely on whether the DSO platform executes its growth plan and achieves a successful recapitalization.
How Buyers Rebuild Normalized EBITDA in 2026
Normalized EBITDA, the earnings figure to which buyers apply their multiple, is not the number on your tax return. It is a reconstructed figure that adds back personal, discretionary, and non-recurring expenses to estimate the economic earnings a buyer is purchasing. The size and defensibility of those add-backs can directly influence enterprise value.
In 2024 through Q2 2026 dental-specific quality-of-earnings work, four add-back categories receive the closest scrutiny. These include owner-doctor above-market compensation, related-party rent adjusted to market, personal-use expenses such as auto, travel, and family payroll, and one-time expenses such as lawsuit settlements or non-recurring build-out costs.
The owner compensation adjustment often deserves particular attention. When an owner’s compensation exceeds the market rate, such as taking 45% of collections when the market rate is 32%, the difference is added to normalized EBITDA. That adjustment directly increases enterprise value at the same multiple. When the owner is already compensated at market rate, there is little or no uplift.
Beyond add-backs, buyers also scrutinize operational metrics that affect the sustainability of your EBITDA. Hygiene metrics and payer mix receive equal scrutiny because they directly affect the quality and durability of the earnings buyers are purchasing. Payer mix can be the single largest driver of intra-band variance in 2026 dental valuations after practice size and specialty. Practices with 60% or more fee-for-service revenue often land in the upper half of published ranges. Practices with 40% or greater Medicaid exposure generally see multiples compressed one to two turns (roughly 15–25%), which narrows the buyer universe significantly.
Worked Example – The $1.5M–$3M Revenue Crossroads Owner: A general dentist with $2.5M revenue and $500K reported pre-tax income receives $229K in documented add-backs. These include excess owner compensation, family payroll, personal vehicle expenses, and a one-time leasehold improvement. The result is $729K adjusted EBITDA and a $4.0M–$5.5M valuation range at 5.5x–7.5x. The same practice with undocumented add-backs might see buyers haircut the EBITDA to $500K or below, which can cost the owner $1.5M or more in enterprise value at the same multiple. A diligence-grade valuation completed before going to market is what often prevents that outcome.
McLerran & Associates builds CPA-led, diligence-grade EBITDA analyses before any practice goes to market, so the numbers tend to hold when buyers scrutinize them and deals are less likely to be re-traded at the finish line. With roughly 2,000 successful practice sales and more than 10,000 practices evaluated, the firm has a detailed view of which add-backs buyers usually accept and which they frequently challenge.
Buyer-Quality Red Flags That Can Shrink Your Realized Multiple
The headline multiple a DSO offers at the letter of intent often differs from the multiple the seller realizes at close, and it can differ even more from the multiple realized over the full holding period of rollover equity. Buyer quality can be the variable most owners underestimate, and in 2026 it can carry more weight than at any point since the pandemic-era consolidation boom.
North American DSO deal activity nearly halved from 2023 to 2025, with total M&A falling from 126 deals to 67 and sponsor-backed buyouts and add-ons dropping from 83 to 46. This contraction reflects a market correction. Platforms built during the pandemic-era boom that were insufficiently integrated, functioning more as collections of individual practices than cohesive operating companies, have reduced their attractiveness to subsequent buyers. That shift has compressed exit multiples and, with them, the value of rollover equity held by selling dentists.
Three specific red flags warrant attention in 2026:
- Undercapitalized DSOs. Some DSO platforms cannot deliver the rollover equity returns of 3–5 times that were promised to selling dentists during the pandemic-era boom, due to the higher interest-rate environment. A DSO that cannot fund its own growth plan can put the seller’s rollover equity at risk of write-down or indefinitely delayed liquidity.
- Post-recapitalization holding-company dilution. Post-recapitalization holding-company equity can materially erode realized value even when the headline price looks attractive. Sellers need to understand the cap table, liquidation preferences, and what happens to equity if the DSO underperforms and is recapitalized at a lower valuation than the deal entered.
- Price re-trades during diligence. During exclusive due diligence in DSO deals, price re-trades of 10–25% multiple compression are not unusual when diligence surprises emerge, including aggressive add-backs or undisclosed liabilities. A seller who entered exclusivity with a single buyer has no competitive leverage to resist a re-trade.
The antidote to all three risks is a structured, competitive sell-side process with vetted buyers. Competition pushes buyers to present their best offer and reduces the leverage imbalance that can enable re-trades. Running a competitive sell-side auction process with a broad pool of targeted buyers typically adds 15–40% to headline price and 25–60% to net after-tax proceeds compared with accepting the first inbound DSO offer. McLerran & Associates vets buyers like investments, underwriting each DSO’s profitability, growth trajectory, management depth, and financial backing, and has blacklisted buyers known for poor post-close environments. Poorly run DSOs never reach the table.
Learn which buyers in your market are well-capitalized, and which to avoid in a free, confidential discovery call.
Frequently Asked Questions
What are typical DSO EBITDA multiples in 2026 for a single-location practice?
For a single-location general dentistry practice, 2026 multiples typically range from approximately 5x to 7x normalized EBITDA for practices with sub-$1M adjusted earnings acquired as DSO add-ons. Multiples can rise to 7x–9x for practices with $1M–$3M EBITDA acquired by regional DSOs. The specific multiple within that range can depend on hygiene retention, payer mix, owner dependence, associate depth, and whether the practice is taken through a competitive bid process. A practice where the owner produces 90% or more of revenue can see a meaningful valuation reduction relative to a practice with strong associate coverage, because buyers cannot underwrite production that walks out the door at close.
How much of a DSO deal is actually paid in cash at closing?
In 2026, cash at close on DSO transactions typically ranges from 60% to 85% of headline enterprise value, depending on practice scale and buyer type. Smaller add-on acquisitions tend toward the higher end of that range. Platform-tier deals with 10 or more locations tend toward the lower end, with 25–35% structured as rollover equity. Beyond the cash-equity-earnout split, sellers also face working-capital adjustments and indemnification escrows, the 10–15% holdback mentioned earlier, that further reduce guaranteed day-one liquidity. The gap between the headline number and the wire at closing can reach 30–50% once all adjustments are accounted for.
What is equity rollover in a DSO deal, and what are the risks?
Equity rollover is the portion of deal consideration paid in shares of the DSO’s parent holding company rather than cash. It is illiquid, typically locked up for 5–7 years until the DSO platform achieves a recapitalization or sale, and its ultimate value depends on the platform’s overall performance, not the seller’s individual practice results. Holding-company equity sits behind the private equity sponsor’s preferred equity with liquidation preferences, meaning common equity holders, including selling dentists, receive proceeds only after those preferences are satisfied. In successful DSO exits, rollover equity has produced meaningful returns. In underperforming platforms, it has been written down or remained illiquid for extended periods. Vetting the DSO’s balance sheet, management team, and growth trajectory before accepting rollover equity can be essential, and this review is a core part of what McLerran & Associates does for every client.
How do normalized EBITDA add-backs affect my practice’s valuation?
Add-backs are the adjustments that convert your reported income into the normalized EBITDA figure buyers use to calculate enterprise value. Every dollar of legitimate, documented add-back increases the earnings base to which the multiple is applied. A $50,000 add-back at an 8x multiple adds $400,000 to enterprise value. Common add-back categories, detailed earlier in this article, include owner compensation adjustments, related-party rent, personal expenses, and one-time costs. The critical qualifier is documentation. Buyers apply a defensibility test to every add-back during quality-of-earnings diligence, and undocumented or aggressive add-backs are frequently removed, which lowers the final multiple. A diligence-grade EBITDA analysis completed before going to market, the kind McLerran & Associates builds for every engagement, helps the add-backs hold up under scrutiny so the deal is less likely to be re-traded at the finish line.
Is a DSO deal always better than selling to a private buyer?
A DSO deal is not always better, and the answer can depend heavily on practice size, the owner’s goals, and the specific deal structure offered. For practices in the $1.5M–$3M revenue range, both paths can be viable. A DSO deal may carry a higher headline multiple, yet a meaningful portion of that value can sit in rollover equity and earnouts rather than guaranteed cash. A private-buyer transaction typically closes at a lower multiple but delivers 100% cash at close with no equity dilution or earnout risk. That structure can produce comparable or superior 5-year net cash outcomes after accounting for the probability-weighted value of contingent DSO consideration. Because McLerran & Associates works both paths in roughly equal measure, the firm can produce a true side-by-side valuation, quantifying the practice’s worth in both markets so owners choose with fuller information rather than a guess.
Conclusion: Turning a Headline Multiple into a Protected Outcome
The 2026 DSO multiple range of roughly 5x to 14x is real, yet it represents a range of enterprise values rather than a range of cash outcomes. The cash an owner actually receives can depend on where within that range a competitive process places the practice, how the deal is structured across cash, equity, and earnouts, how defensible the normalized EBITDA add-backs are under diligence, and whether the buyer is well-capitalized enough to support its commitments over the full holding period of rollover equity.
Owners who enter the process with a single DSO offer, an undocumented EBITDA analysis, or no competitive tension can leave significant value on the table and sometimes partner with buyers who cannot deliver on the equity component of the deal. Owners who run a structured sell-side auction with vetted buyers and a diligence-grade valuation more often capture the upper end of the range.
McLerran & Associates has guided owners through this process, the roughly 2,000 successful sales mentioned earlier, closing approximately $2 billion in transaction volume with an ~85–90% transaction rate, compared with an industry norm closer to 35–40%. The firm works exclusively on the sell side, runs a competitive bid process that typically generates around 10 offers in 45–60 days, and vets every buyer before they reach the table. That process can be what converts a headline multiple into a maximized, protected outcome.
Discuss what a competitive process could deliver for your practice in a free, confidential call with McLerran & Associates. Call (512) 900-7989 or email info@dentaltransitions.com.
Not ready to sell yet? Join the McLerran M&A Summit on October 29–30, 2026, a dental-only event built for owners who have not decided yet. Attend to get educated on deal structures, EBITDA, and the 2026 buyer landscape before committing to anything, and receive a complimentary practice valuation (a $2,500 value) along with 4 CE credits. Reserve your seat here.
